Scarica l'app Stockscreener
68.45
2.34%
-1.64
Dopo l'orario di chiusura:
68.21
-0.24
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$70.09
Aprire:
$69.51
Volume 24 ore:
1.87M
Relative Volume:
0.78
Capitalizzazione di mercato:
$9.30B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-49.24
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
-0.22%
1M Prestazione:
+65.90%
6M Prestazione:
+334.88%
1 anno Prestazione:
+213.27%
Intervallo 1D:
$68.17
$70.51
Intervallo di 1 settimana:
$65.46
$72.36
Portata 52W:
$9.57
$72.36
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
68.45 | 9.52B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc - MarketBeat
WINTON GROUP Ltd Invests $660,000 in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation - Nasdaq
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Arrowhead Pharma (ARWR) Receives Raised Price Target from RBC Capital | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD - Investing.com
Arrowhead Pharma stock price target raised to $80 from $52 at RBC Capital - Investing.com Canada
Arrowhead Pharmaceuticals (ARWR) Valuation Check as ARO-MAPT Enters First Human Trial in Alzheimer’s Treatment - Yahoo Finance
History Review: Can Arrowhead Pharmaceuticals Inc stock surprise with earnings upsideJuly 2025 Closing Moves & Verified Momentum Stock Watchlist - moha.gov.vn
Michael Perry Sells 16,250 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
ARWR: B of A Securities Raises Price Target Amid Maintained Buy Rating | ARWR Stock News - GuruFocus
Bank of America Issues Positive Forecast for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownTime to Sell? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial - ts2.tech
Arrowhead Pharmaceuticals Flourishes with Key Milestones and Growth Projections - StocksToTrade
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins - ts2.tech
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial - Investing.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year HighTime to Buy? - MarketBeat
Arrowhead Hits the Mark - Los Angeles Business Journal
Arrowhead’s Plozasiran Garners FDA Breakthrough Recognition - timothysykes.com
Arrowhead (ARWR) Begins Trials for Alzheimer's Treatment - GuruFocus
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Yahoo Finance
Marshall Wace LLP Grows Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Norges Bank Invests $30.41 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
(ARWR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Edgestream Partners L.P. Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5%What's Next? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Price Target Increased by 17.24% to 59.24 - Nasdaq
Franklin Resources Inc. Purchases Shares of 81,226 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR) and Humana (HUM) - The Globe and Mail
Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Therapy Designation for Plozasiran - Sahm
How Arrowhead Pharmaceuticals Inc. (HDP1) stock reacts to Fed tighteningEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
How analysts revise price targets for Arrowhead Pharmaceuticals Inc. (HDP1) stockPortfolio Value Report & Reliable Price Breakout Alerts - Newser
Fisher Asset Management LLC Has $7.14 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockWeekly Loss Report & Long-Term Capital Growth Strategies - Newser
Is Arrowhead Pharmaceuticals Inc. (HDP1) stock cheap vs fundamentalsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Breakthrough Approved: FDA approves pioneering FCS drug by Pasadena company - Pasadena Weekly
HC Wainwright Issues Pessimistic Estimate for ARWR Earnings - MarketBeat
What is HC Wainwright's Estimate for ARWR Q2 Earnings? - MarketBeat
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock is favored by hedge fundsJuly 2025 Summary & Low Drawdown Trading Strategies - Newser
Arrowhead Pharmaceuticals Poised for Growth Following Breakthrough FDA Approvals - StocksToTrade
ARWR’s Meteoric Rise: Can It Sustain? - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High After Analyst Upgrade - MarketBeat
ARWR: Plozasiran launch, pipeline advances, and strong partnerships drive growth and innovation - TradingView
Arrowhead (ARWR) Stock Sees 9.7% Rise Following Market Activity - GuruFocus
Arrowhead Pharmaceuticals Soars with FDA Breakthrough Therapy Designation - timothysykes.com
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):